1,500 reports of this reaction
3.8% of all ERYTHROPOIETIN reports
#2 most reported adverse reaction
ANAEMIA is the #2 most commonly reported adverse reaction for ERYTHROPOIETIN, manufactured by Janssen Products, LP. There are 1,500 FDA adverse event reports linking ERYTHROPOIETIN to ANAEMIA. This represents approximately 3.8% of all 39,177 adverse event reports for this drug.
Patients taking ERYTHROPOIETIN who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is moderately reported among ERYTHROPOIETIN users, representing a notable but not dominant share of adverse events.
In addition to anaemia, the following adverse reactions have been reported for ERYTHROPOIETIN:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 1,500 FDA reports for ERYTHROPOIETIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 3.8% of all adverse event reports for ERYTHROPOIETIN, making it one of the most commonly reported side effect.
If you experience anaemia while taking ERYTHROPOIETIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.